You are here: Industry Insights > source

News List

Popular APIs of the Year at Pharmasources.com PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com？
Popular Products and Companies at PharmaSources.com (June 2024) PharmaSources
June 25, 2024
Popular Products and Companies at PharmaSources.com
Pharma Sources Insight June 2024: Globalization on the GO! Pharma Sources Insight
June 29, 2024
Pharma Sources Insight JUNE 2024 focuses on wearable delivery system, sythetic biology, pharmaceutical globalization and more.
An Overview to 2023 Pharmaceutical Industry by PharmaSources Experts PharmaSources
March 07, 2024
20 Selected Articles by PharmaSources Experts in 2023
Becoming Contracted Authors of PharmaSources PharmaSources.com
February 26, 2024
Join PharmaSources.com to share your insights into the pharmaceutical industry with hundreds of industrial KOLs in a league!
Popular Products and Companies at PharmaSources.com (January 2024) PharmaSources
February 23, 2024
Popular Products and Companies at PharmaSources.com
Pharma Sources Insight January 2024: Pharmaceutical Industry in 2024 - Flexible Production, Innovative Drugs and Personalized Medicine Pharma Sources Insight
January 15, 2024
Pharmaceutical Industry Outlook in 2024.
Monthly News Review of PharmaSources (February) - Business Caicai/PharmaSources
March 14, 2023
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
Monthly Pharma News Review of PharmaSources (February) - Chinese Drug review and approval Caicai/PharmaSources
March 14, 2023
The anti-PD-L1 monoclonal antibody Adebrelimab from Hengrui Pharmaceuticals was approved for marketing, and the Class 3 chemotherapy Limaprost tablets from Sino Biopharm were approved for marketing.
Monthly News Review of PharmaSources (February) - R&D Caicai/PharmaSources
March 13, 2023
In R&D, Chipscreen chidamide Ⅲ test reaches preset indicators, the company plans to submit an application for the marketing of a new indication.